Voxzogo injection, for subcutaneous use
1.
2.
3.
4.
1.
2.
3.
4.
1.
2.
eGFR <60 mL/min/1.73 m2
3.
4.
5.
1.
2.
|
Vial Strength for Reconstitution* |
Dose |
Injection Volume |
10 ~ 11 kg |
0.4 mg |
0.24 mg |
0.3 mL |
12 ~ 16 kg |
0.56 mg |
0.28 mg |
0.35 mL |
17 ~ 21 kg |
0.56 mg |
0.32 mg |
0.4 mL |
|
Vial Strength for Reconstitution* |
Dose |
Injection Volume |
22 ~ 32 kg |
0.56 mg |
0.4 mg |
0.5 mL |
33 ~ 43 kg |
1.2 mg |
0.5 mg |
0.25 mL |
44 ~ 59 kg |
1.2 mg |
0.6 mg |
0.3 mL |
60 ~ 89 kg |
1.2 mg |
0.7 mg |
0.35 mL |
|
1.2 mg |
0.8 mg |
0.4 mL |
* |
1.
2.
3.
1. Product Information: Voxzogo [cited 2023 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf
2.
3. https://medlineplus.gov/genetics/
4. https://www.pharmaceutic.idv.tw/prescription-view/Vosoritide